Exelixis Inc.

Find Ratings Reports
EXEL : NASDAQ : Health Technology
$22.92 -0.39 | -1.7%
Today's Range: 22.54 - 23.82
Avg. Daily Volume: 2797000.0
03/23/18 - 2:58 PM ET

Financial Analysis

EXELIXIS INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. EXELIXIS INC is extremely liquid. Currently, the Quick Ratio is 4.08 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 219.04% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.

Income Statement Q4 FY17 Q4 FY16
Net Sales ($mil)120.0777.58
EBITDA ($mil)37.7839.17
EBIT ($mil)37.4338.93
Net Income ($mil)38.4935.12

Balance Sheet Q4 FY17 Q4 FY16
Cash & Equiv. ($mil)388.28419.8
Total Assets ($mil)655.29597.54
Total Debt ($mil)0.0189.12
Equity ($mil)284.9689.32

Profitability Q4 FY17 Q4 FY16
Gross Profit Margin31.4650.49
EBITDA Margin31.4650.49
Operating Margin31.1750.17
Sales Turnover0.690.32
Return on Assets23.53-11.75
Return on Equity54.12-78.62
Debt Q4 FY17 Q4 FY16
Current Ratio4.211.74
Interest Expense0.04.49
Interest Coverage0.08.68

Share Data Q4 FY17 Q4 FY16
Shares outstanding (mil)296.21289.92
Div / share0.00.0
Book value / share0.960.31
Institutional Own % n/a n/a
Avg Daily Volume2893534.03434450.0


HOLD. This stock's P/E ratio indicates a premium compared to an average of 47.18 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 25.66. For additional comparison, its price-to-book ratio of 25.73 indicates a significant premium versus the S&P 500 average of 3.28 and a significant premium versus the industry average of 20.65. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, EXELIXIS INC proves to trade at a premium to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
EXEL 50.51 Peers 47.18   EXEL 44.27 Peers 25.10

Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.

EXEL is trading at a valuation on par with its peers.


Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

EXEL is trading at a significant premium to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
EXEL 18.97 Peers 25.68   EXEL 4.13 Peers 0.38

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

EXEL is trading at a significant premium to its peers.


Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

EXEL trades at a significant premium to its peers.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
EXEL 25.73 Peers 20.65   EXEL 248.48 Peers -0.73

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

EXEL is trading at a premium to its peers.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

EXEL is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
EXEL 16.20 Peers 78.78   EXEL 136.33 Peers 472.09

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

EXEL is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

EXEL significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades